Trial Outcomes & Findings for Trigger Point Injections in Anterior Cervical Surgery (NCT NCT04640896)

NCT ID: NCT04640896

Last Updated: 2026-08-13

Results Overview

Milligrams morphine equivalents (MME)

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

60 participants

Primary outcome timeframe

6 hours after intervention

Results posted on

2026-08-13

Participant Flow

Participant milestones

Participant milestones
Measure
Lidocaine Skin Wheal
They will receive an injection of lidocaine in the skin over the area of the trigger points. While this causes a small area of numbness, it is not a trigger point injection. Lidocaine skin wheal: Patients in the control group will receive a small skin wheal of lidocaine. This will keep the patient blinded to the study group they are in since all patients will receive an injection. However, this skin wheal is not considered a trigger point injection.
Trigger Point Injection With Normal Saline
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.9% Normal Saline + intra- and postoperative standardized analgesia regimen Trigger point injection with normal saline: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
Trigger Point Injection With Bupivacaine
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.25% bupivacaine hydrochloride + intra- and postoperative standardized analgesia regimen Trigger point injection with bupivacaine: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
Overall Study
STARTED
19
23
18
Overall Study
COMPLETED
19
23
18
Overall Study
NOT COMPLETED
0
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Trigger Point Injections in Anterior Cervical Surgery

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Lidocaine Skin Wheal
n=19 Participants
They will receive an injection of lidocaine in the skin over the area of the trigger points. While this causes a small area of numbness, it is not a trigger point injection. Lidocaine skin wheal: Patients in the control group will receive a small skin wheal of lidocaine. This will keep the patient blinded to the study group they are in since all patients will receive an injection. However, this skin wheal is not considered a trigger point injection.
Trigger Point Injection With Normal Saline
n=23 Participants
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.9% Normal Saline + intra- and postoperative standardized analgesia regimen Trigger point injection with normal saline: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
Trigger Point Injection With Bupivacaine
n=18 Participants
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.25% bupivacaine hydrochloride + intra- and postoperative standardized analgesia regimen Trigger point injection with bupivacaine: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
Total
n=60 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=1 Participants
0 Participants
n=1 Participants
0 Participants
n=1 Participants
0 Participants
n=2 Participants
Age, Categorical
Between 18 and 65 years
16 Participants
n=1 Participants
18 Participants
n=1 Participants
10 Participants
n=1 Participants
44 Participants
n=2 Participants
Age, Categorical
>=65 years
3 Participants
n=1 Participants
5 Participants
n=1 Participants
8 Participants
n=1 Participants
16 Participants
n=2 Participants
Sex: Female, Male
Female
12 Participants
n=1 Participants
7 Participants
n=1 Participants
8 Participants
n=1 Participants
27 Participants
n=2 Participants
Sex: Female, Male
Male
7 Participants
n=1 Participants
16 Participants
n=1 Participants
10 Participants
n=1 Participants
33 Participants
n=2 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=1 Participants
0 Participants
n=1 Participants
0 Participants
n=1 Participants
0 Participants
n=2 Participants
Race (NIH/OMB)
Asian
1 Participants
n=1 Participants
0 Participants
n=1 Participants
1 Participants
n=1 Participants
2 Participants
n=2 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=1 Participants
0 Participants
n=1 Participants
0 Participants
n=1 Participants
0 Participants
n=2 Participants
Race (NIH/OMB)
Black or African American
7 Participants
n=1 Participants
7 Participants
n=1 Participants
6 Participants
n=1 Participants
20 Participants
n=2 Participants
Race (NIH/OMB)
White
11 Participants
n=1 Participants
16 Participants
n=1 Participants
11 Participants
n=1 Participants
38 Participants
n=2 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=1 Participants
0 Participants
n=1 Participants
0 Participants
n=1 Participants
0 Participants
n=2 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=1 Participants
0 Participants
n=1 Participants
0 Participants
n=1 Participants
0 Participants
n=2 Participants

PRIMARY outcome

Timeframe: 6 hours after intervention

Milligrams morphine equivalents (MME)

Outcome measures

Outcome measures
Measure
Lidocaine Skin Wheal
n=19 Participants
They will receive an injection of lidocaine in the skin over the area of the trigger points. While this causes a small area of numbness, it is not a trigger point injection. Lidocaine skin wheal: Patients in the control group will receive a small skin wheal of lidocaine. This will keep the patient blinded to the study group they are in since all patients will receive an injection. However, this skin wheal is not considered a trigger point injection.
Trigger Point Injection With Normal Saline
n=23 Participants
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.9% Normal Saline + intra- and postoperative standardized analgesia regimen Trigger point injection with normal saline: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
Trigger Point Injection With Bupivacaine
n=18 Participants
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.25% bupivacaine hydrochloride + intra- and postoperative standardized analgesia regimen Trigger point injection with bupivacaine: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
Opioid Consumption in the First 6 Hour Period After Intervention (Trigger Point Injection/Sham)
17.7 MME
Interval 0.0 to 60.0
15.9 MME
Interval 0.0 to 49.5
18.3 MME
Interval 0.0 to 45.0

PRIMARY outcome

Timeframe: 12 hours after intervention

Milligrams morphine equivalents (MME)

Outcome measures

Outcome measures
Measure
Lidocaine Skin Wheal
n=19 Participants
They will receive an injection of lidocaine in the skin over the area of the trigger points. While this causes a small area of numbness, it is not a trigger point injection. Lidocaine skin wheal: Patients in the control group will receive a small skin wheal of lidocaine. This will keep the patient blinded to the study group they are in since all patients will receive an injection. However, this skin wheal is not considered a trigger point injection.
Trigger Point Injection With Normal Saline
n=23 Participants
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.9% Normal Saline + intra- and postoperative standardized analgesia regimen Trigger point injection with normal saline: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
Trigger Point Injection With Bupivacaine
n=18 Participants
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.25% bupivacaine hydrochloride + intra- and postoperative standardized analgesia regimen Trigger point injection with bupivacaine: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
Opioid Consumption in the First 12 Hour Period After Intervention (Trigger Point Injection/Sham)
10.3 MME
Interval 0.0 to 37.5
7.8 MME
Interval 0.0 to 30.0
5.7 MME
Interval 0.0 to 19.5

PRIMARY outcome

Timeframe: 24 hours after intervention

Milligrams morphine equivalents

Outcome measures

Outcome measures
Measure
Lidocaine Skin Wheal
n=19 Participants
They will receive an injection of lidocaine in the skin over the area of the trigger points. While this causes a small area of numbness, it is not a trigger point injection. Lidocaine skin wheal: Patients in the control group will receive a small skin wheal of lidocaine. This will keep the patient blinded to the study group they are in since all patients will receive an injection. However, this skin wheal is not considered a trigger point injection.
Trigger Point Injection With Normal Saline
n=23 Participants
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.9% Normal Saline + intra- and postoperative standardized analgesia regimen Trigger point injection with normal saline: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
Trigger Point Injection With Bupivacaine
n=18 Participants
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.25% bupivacaine hydrochloride + intra- and postoperative standardized analgesia regimen Trigger point injection with bupivacaine: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
Opioid Consumption in the First 24 Hour Period After Intervention (Trigger Point Injection/Sham)
10.9 MME
Interval 0.0 to 42.0
12.5 MME
Interval 0.0 to 45.0
12.8 MME
Interval 0.0 to 45.0

SECONDARY outcome

Timeframe: 6 hours after intervention

Pain score will be assessed using visual analog scale. 0 indicates no pain and 10 indicates the worst possible pain.

Outcome measures

Outcome measures
Measure
Lidocaine Skin Wheal
n=19 Participants
They will receive an injection of lidocaine in the skin over the area of the trigger points. While this causes a small area of numbness, it is not a trigger point injection. Lidocaine skin wheal: Patients in the control group will receive a small skin wheal of lidocaine. This will keep the patient blinded to the study group they are in since all patients will receive an injection. However, this skin wheal is not considered a trigger point injection.
Trigger Point Injection With Normal Saline
n=23 Participants
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.9% Normal Saline + intra- and postoperative standardized analgesia regimen Trigger point injection with normal saline: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
Trigger Point Injection With Bupivacaine
n=18 Participants
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.25% bupivacaine hydrochloride + intra- and postoperative standardized analgesia regimen Trigger point injection with bupivacaine: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
Pain Score at 6 Hours After Intervention (Trigger Point Injection/Sham).
3.8 Numerical pain score 1-10 (10 is worse)
Interval 0.0 to 8.0
5.3 Numerical pain score 1-10 (10 is worse)
Interval 1.0 to 10.0
5.9 Numerical pain score 1-10 (10 is worse)
Interval 0.0 to 10.0

SECONDARY outcome

Timeframe: 12 hours after intervention

Pain score will be assessed using visual analog scale. 0 indicates no pain and 10 indicates the worst possible pain.

Outcome measures

Outcome measures
Measure
Lidocaine Skin Wheal
n=19 Participants
They will receive an injection of lidocaine in the skin over the area of the trigger points. While this causes a small area of numbness, it is not a trigger point injection. Lidocaine skin wheal: Patients in the control group will receive a small skin wheal of lidocaine. This will keep the patient blinded to the study group they are in since all patients will receive an injection. However, this skin wheal is not considered a trigger point injection.
Trigger Point Injection With Normal Saline
n=23 Participants
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.9% Normal Saline + intra- and postoperative standardized analgesia regimen Trigger point injection with normal saline: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
Trigger Point Injection With Bupivacaine
n=18 Participants
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.25% bupivacaine hydrochloride + intra- and postoperative standardized analgesia regimen Trigger point injection with bupivacaine: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
Pain Score at 12 Hours After Intervention (Trigger Point Injection/Sham)
3.8 Numerical pain score 1-10 (10 is worse)
Interval 0.0 to 8.0
4.9 Numerical pain score 1-10 (10 is worse)
Interval 0.0 to 10.0
5.5 Numerical pain score 1-10 (10 is worse)
Interval 0.0 to 10.0

SECONDARY outcome

Timeframe: 24 hours after intervention

Pain score will be assessed using visual analog scale. 0 indicates no pain and 10 indicates the worst possible pain.

Outcome measures

Outcome measures
Measure
Lidocaine Skin Wheal
n=19 Participants
They will receive an injection of lidocaine in the skin over the area of the trigger points. While this causes a small area of numbness, it is not a trigger point injection. Lidocaine skin wheal: Patients in the control group will receive a small skin wheal of lidocaine. This will keep the patient blinded to the study group they are in since all patients will receive an injection. However, this skin wheal is not considered a trigger point injection.
Trigger Point Injection With Normal Saline
n=23 Participants
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.9% Normal Saline + intra- and postoperative standardized analgesia regimen Trigger point injection with normal saline: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
Trigger Point Injection With Bupivacaine
n=18 Participants
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.25% bupivacaine hydrochloride + intra- and postoperative standardized analgesia regimen Trigger point injection with bupivacaine: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
Pain Score at 24 Hours After Intervention (Trigger Point Injection/Sham)
3.9 Numerical pain score 1-10 (10 is worse)
Interval 0.0 to 8.0
4.3 Numerical pain score 1-10 (10 is worse)
Interval 0.0 to 10.0
4.1 Numerical pain score 1-10 (10 is worse)
Interval 0.0 to 10.0

SECONDARY outcome

Timeframe: Through hospital discharge, an average of 2 days

Measured in days and hours

Outcome measures

Outcome measures
Measure
Lidocaine Skin Wheal
n=19 Participants
They will receive an injection of lidocaine in the skin over the area of the trigger points. While this causes a small area of numbness, it is not a trigger point injection. Lidocaine skin wheal: Patients in the control group will receive a small skin wheal of lidocaine. This will keep the patient blinded to the study group they are in since all patients will receive an injection. However, this skin wheal is not considered a trigger point injection.
Trigger Point Injection With Normal Saline
n=23 Participants
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.9% Normal Saline + intra- and postoperative standardized analgesia regimen Trigger point injection with normal saline: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
Trigger Point Injection With Bupivacaine
n=18 Participants
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.25% bupivacaine hydrochloride + intra- and postoperative standardized analgesia regimen Trigger point injection with bupivacaine: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
Post-operative Length of Stay
1.05 Days
Interval 0.0 to 4.0
1.43 Days
Interval 0.0 to 12.0
1.22 Days
Interval 0.0 to 6.0

Adverse Events

Lidocaine Skin Wheal

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Trigger Point Injection With Normal Saline

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Trigger Point Injection With Bupivacaine

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Eduard Shaykhinurov, Research Manager

GW Medicine

Phone: 2028234259

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place